Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maribavir versus valganciclovir for CMV infection after hematopoietic stem cell transplant
2015-004726-34Phase 3Completed
- Sponsor
- Takeda
- Start
- Jun 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cytomegalovirus disease (CMV) comparing Maribavir with Valcyte (2 arms). Primary endpoint: Confirmed clearance of plasma CMV DNA. Started Jun 2017; status: completed.
02
Drugs
maribavirvalganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2015-004726-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004726-34.